NASDAQ
ZLAB
ADR/GDR
Zai Lab Limited
USD 18.1800
0.3000 (+1.6779%)
After Hours: USD 18.160 -0.010 (-0.055%)
Last updated: 19 Jun 2026 6:52:27 AM
DelayedDelayed at least 15 minutes
Last updated: 19 Jun 2026 6:52:27 AM (Singapore Time)
NASDAQZLAB ADR/GDR
Zai Lab Limited
DelayedDelayed at least 15 minutes
USD 18.1800
After Hours: USD 18.1600 -0.0100 (-0.0550%)
+1.6779%
+ USD 0.3000
Open
USD 18.4500
Prev. Close
USD 17.8800
Bid
USD 17.2800
Bid Volume
500
Ask
USD 18.8200
Ask Volume
100
Total Volume
978,130.264
18.1500
Day's Range
19.1100
15.9600
52 Weeks Range
41.2000
SHOW ALL KEY STATISTICS
ZLAB Chart
Delayed
Chart data is delayed at least 15 minutes.
Created with Highcharts 9.3.2Chart context menu23. Mar30. Mar6. Apr13. Apr20. Apr27. Apr4. May11. May18. May25. May1. Jun8. Jun15. Jun161820222426fundsupermart.com
Stock Information
Market Cap
USD 2.04 billion
Share Outstanding
112.35 million
30 Days Average Volume
0.91 million
Product Currency
USD
Valuations
Earning Per Share
USD -1.600
Price-to-Earnings Ratio (PE)
-
Historical Avg. PE Ratio
-
Price-to-Book Ratio (PB)
3.085
Price-to-Sales Ratio (PS)
4.419
Price/Earnings-to-Growth Ratio
-
Selected Financial Data
Free Cash Flow
USD -164.21 million
Debt-to-Equity Ratio
0.019
Current Ratio
2.449
Quick Ratio
1.941
Return On Equity (%)
-22.56
Return On Assets (%)
-14.89
Dividend Info
Hist. Annual Dividend
-
Forward Div. Yield (%)
-
Pay-out Ratio (%)
-
Last Div. Ex Date
-
Next Div. Ex Date
-
Financial Information MORE
Created with Highcharts 9.3.2Chart context menuRevenueNet Income20252024202320222021-750.00M-500.00M-250.00M0250.00M500.00M
(USD)
2025 YOY Change
2024 YOY Change
2023 YOY Change
2022 YOY Change
2021 YOY Change
Revenue
460.16M
15.33%
398.99M
49.59%
266.72M
24.03%
215.04M
49.01%
144.31M
194.77%
Operating Income
-223.57M
-18.39%
-273.95M
-26.78%
-374.14M
-7.47%
-404.36M
-42.24%
-700.06M
131.96%
Net Income
-175.54M
-31.72%
-257.10M
-23.17%
-334.62M
-24.51%
-443.29M
-37.08%
-704.47M
161.98%
About Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Sector
Healthcare
Industry Classification
Biotechnology
Product Type
-
Sales
USD 460.16 million
Market Cap
USD 2.04 billion
Net Income
USD -175,537,000
Share Outstanding
112.35 million
Fiscal Year End
31 Dec 2026
52 Weeks Range
USD 15.9600 - USD 41.2000
Employees
1,784
30 Days Average Volume
0.91 million
Payment Method
Included under Cash Yes
Included under CPFIS OA No
Included under CPFIS SA No
Included under SRS No
Upcoming Exchange Holidays MORE
United States (US)
18Jun
Juneteenth National Independence Day
02Jul
Independence Day (Observed)
06Sep
Labor Day
25Nov
Thanksgiving Day
26Nov
Day after Thanksgiving Day (Half-Day Trading)
Tools
newCalculatorIcon
Stock Calculator
newCalculatorIcon
Stock Returns
newScreenerSelectorIcon
Stock Screener
newCalculatorIcon
Intrinsic Value Calculator
newGainerIcon
Top Gainer Loser